E-cigarettes have been marketed as a suitable alternative to smoking. They reportedly don’t cause the negative health consequences associated with conventional cigarettes. However, a recent report published on Oncotarget has disputed this claim and revealed that e-cigarettes have their shortcomings too.
Gum Tissue Damage
Researchers from the University of Rochester Medical Center showed that e-cigarettes are just as damaging to gum tissues as conventional cigarettes. The research was the first to determine the effects of e-cigarettes on oral health. It was led by Irfan Rahman, Ph.D in conjunction with fellow professors and students. Researchers have always blamed the chemicals used in e-cigarettes for these adverse oral side-effects. However, the research suggests otherwise. According to the report, the smoke from e-cigarettes triggers the release of inflammatory proteins in the gum tissues. Inflammation is reportedly the first phase of a myriad of other oral diseases.The researchers also established that the extent of these adverse oral health effects depends on how much and how often one “vapes”. The report also claims that different flavors have varying effects depending on factors such as quality and ingredients.
This experiment was conducted using a non-smoker’s human gum tissue designed in 3D to emulate the real thing. This tissue was exposed to vapor from e-cigarettes, and over time the researchers noted that flavors in the “e-juice” trigerred the release of the aforementioned inflammatory proteins.However, the researchers also noted that this research was short-term and there is need for long-term experimentation to learn more. The goal is to sensitize the public on the harms of e-cigarettes as well as to motivate manufacturers to improve the quality of their products.
Oncotarget – A Reliable Oncology Journal
This report was first published on Oncotarget, a reputable open-source weekly oncology journal. The online journal accepts a wide array of research papers touching on diverse aspects of oncology, and it has been instrumental in centralizing data. It has been operational since 2010, and in 2016 it had an impact factor of 5.168.Oncotarget is overseen by editors-in-chief Mikhail Blagosklonny and Andrei V. Gudkov, both of who are reputable scientists and researchers specializing in oncology.